Non-vitamin K-dependent clotting factors during oral anticoagulant treatment.

Laboratory tests during direct oral anticoagulant treatment.

Nonvitamin K antagonist oral anticoagulant use in patients with renal impairment.

Nonvitamin K antagonist oral anticoagulant activity: challenges in measurement and reversal.

Laboratory tests during direct oral anticoagulant treatment? Authors' reply.

Survey of oral anticoagulant treatment in children.

Clotting factors: Stretching time.

Oral anticoagulant drugs.

Oral anticoagulant treatment in geriatric patients with nonvalvular atrial fibrillation in the era of direct oral anticoagulant agents.

Oral anticoagulant drugs.

A clinical dilemma about a new oral anticoagulant treatment.

Pharmacokinetics and Pharmacodynamics of Edoxaban, a Non-Vitamin K Antagonist Oral Anticoagulant that Inhibits Clotting Factor Xa.

Risk factors for bleeding after oral surgery in patients who continued using oral anticoagulant therapy.

Oral contraceptives, blood clotting and thrombosis.

Pharmacokinetics and Pharmacodynamics of the Nonvitamin K Antagonist Oral Anticoagulant Edoxaban When Administered Alone or After Switching from Rivaroxaban or Dabigatran Etexilate in Healthy Subjects.

Bleeding complications during anticoagulant treatment in patients with cancer.

Clotting factor changes during the first cycle of oral contraceptive use.

Anticoagulant use during breastfeeding.

Haematemesis during oral aminophylline treatment.

Incidence, mortality, and risk factors for oral anticoagulant-associated intracranial hemorrhage in patients with atrial fibrillation.

Edoxaban (Savaysa)--The Fourth New Oral Anticoagulant.

Anticoagulant treatment in sarcoidosis.

The control of oral anticoagulant therapy.

Monitoring anticoagulant therapy with new oral agents.

Rheological measurements of fibrin gels during clotting.

Suggest Documents

Laboratory tests during direct oral anticoagulant treatment.

Nonvitamin K antagonist oral anticoagulant use in patients with renal impairment.

Nonvitamin K antagonist oral anticoagulant activity: challenges in measurement and reversal.

Laboratory tests during direct oral anticoagulant treatment? Authors' reply.

Survey of oral anticoagulant treatment in children.

Clotting factors: Stretching time.

Oral anticoagulant drugs.

Oral anticoagulant treatment in geriatric patients with nonvalvular atrial fibrillation in the era of direct oral anticoagulant agents.

Oral anticoagulant drugs.

A clinical dilemma about a new oral anticoagulant treatment.

Pharmacokinetics and Pharmacodynamics of Edoxaban, a Non-Vitamin K Antagonist Oral Anticoagulant that Inhibits Clotting Factor Xa.

Risk factors for bleeding after oral surgery in patients who continued using oral anticoagulant therapy.

Oral contraceptives, blood clotting and thrombosis.

Pharmacokinetics and Pharmacodynamics of the Nonvitamin K Antagonist Oral Anticoagulant Edoxaban When Administered Alone or After Switching from Rivaroxaban or Dabigatran Etexilate in Healthy Subjects.

Bleeding complications during anticoagulant treatment in patients with cancer.

Clotting factor changes during the first cycle of oral contraceptive use.

Anticoagulant use during breastfeeding.

Haematemesis during oral aminophylline treatment.

Incidence, mortality, and risk factors for oral anticoagulant-associated intracranial hemorrhage in patients with atrial fibrillation.

Edoxaban (Savaysa)--The Fourth New Oral Anticoagulant.

Anticoagulant treatment in sarcoidosis.

The control of oral anticoagulant therapy.

Monitoring anticoagulant therapy with new oral agents.

Rheological measurements of fibrin gels during clotting.

Non-vitamin K-dependent clotting factors during oral anticoagulant treatment.

Recommend Documents

Follow Us